Cara Therapeutics appoints Helen M. Boudreau, former Novartis CFO, to board

Tvardi Therapeutics, Inc.

Appointed effective August 2, 2023; term expires at 2024 annual meeting.
Boudreau brings 30+ years experience; previously COO of Bill & Melinda Gates Medical Research Institute (2018-2019).
Received initial stock option grant with Black-Scholes value of $350,000, vesting quarterly over three years.
Will receive annual cash retainer of $50k for director service and $10k for audit committee (pro-rated 2023).
Appointed to audit committee; currently serves on boards of Premier Inc., Shattuck Labs, and Rallybio.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Helen M. Boudreau

member of the Board

TVRD · Tvardi Therapeutics, Inc.

Effective: 2023-08-02
Filed: August 3, 2023, 7:59 PM ET

On August 2, 2023, upon the recommendation of its nominating and corporate governance committee, the Board of Directors (the “Board”) of Cara Therapeutics, Inc. (the “Company”) appointed Helen M. Boudreau, M.B.A. to serve as a member of the Board effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Helen M. Boudreau was appointed as member of the Board at Tvardi Therapeutics, Inc..

Action: appointed
Role: member of the Board

Exact text from the filing

On August 2, 2023, upon the recommendation of its nominating and corporate governance committee, the Board of Directors (the “Board”) of Cara Therapeutics, Inc. (the “Company”) appointed Helen M. Boudreau, M.B.A. to serve as a member of the Board effective immediately.

View on SEC.gov

Tvardi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-087025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.